To include your compound in the COVID-19 Resource Center, submit it here.

Selectivity sets off $37M series A for mTOR company Aeovian

Selectivity data for Aeovian’s mTORC1 inhibitor attracted venBio, Sofinnova Investments to lead series A

Preclinical selectivity data for Aeovian’s mTORC1 inhibitor prompted venBio and Sofinnova Investments to co-lead the biotech’s $37 million series A after long eyeing the space.

“mTORC1 selective inhibition has been a Holy Grail target in big pharma for a long time,” venBio’s Richard Gaster told BioCentury. The master

Read the full 473 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers